Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Teva Pharmaceuticals Agrees to $4.25 Billion Settlement of Opioid Claims

  • Post author:PacConAdmin
  • Post published:July 27, 2022
  • Post category:Drug Industry Daily

Teva Pharmaceuticals has agreed to a proposed $4.25 billion settlement to resolve lawsuits brought by more than 2,500 U.S. cities, counties, states and Native American tribes over the company’s alleged…

Continue ReadingTeva Pharmaceuticals Agrees to $4.25 Billion Settlement of Opioid Claims

Avadel Sues FDA Claiming Botched Approval Process for Narcolepsy Drug Lumryz

  • Post author:PacConAdmin
  • Post published:July 27, 2022
  • Post category:Drug Industry Daily

Avadel Pharmaceuticals has sued the FDA and HHS for holding up review and approval of its Lumryz narcolepsy drug after making administrative errors in the approval process, including delaying the…

Continue ReadingAvadel Sues FDA Claiming Botched Approval Process for Narcolepsy Drug Lumryz

FDA Slaps Bi-Coastal Pharma for Complaint Handling, QA Problems

  • Post author:PacConAdmin
  • Post published:July 27, 2022
  • Post category:Drug Industry Daily

The FDA has sent New Jersey-based Bi-Coastal Pharma International a warning letter, insisting that the company complete a complaint investigation rather than passing the buck to its now-defunct supplier. Source:…

Continue ReadingFDA Slaps Bi-Coastal Pharma for Complaint Handling, QA Problems

Episciences Gets Form 483 for Lack of Testing, Deficient Cleaning Procedures

  • Post author:PacConAdmin
  • Post published:July 26, 2022
  • Post category:Drug Industry Daily

Boise, Idaho-based Episciences was issued an 8-observation Form 483 for missing testing procedures, deficient cleaning and other quality lapses. Source: Drug Industry Daily

Continue ReadingEpisciences Gets Form 483 for Lack of Testing, Deficient Cleaning Procedures

Federal Court Rules Against Two Pfizer Copay Plans, Citing Anti-Kickback Statute

  • Post author:PacConAdmin
  • Post published:July 26, 2022
  • Post category:Drug Industry Daily

A three-judge panel has rejected Pfizer’s plan to help Medicare patients pay for one of its most expensive drugs, citing the federal anti-kickback statute. Source: Drug Industry Daily

Continue ReadingFederal Court Rules Against Two Pfizer Copay Plans, Citing Anti-Kickback Statute

FDA Gives Priority Review to Biogen’s Tofersen for Rare Form of ALS

  • Post author:PacConAdmin
  • Post published:July 26, 2022
  • Post category:Drug Industry Daily

The FDA has granted priority review status to Biogen’s New Drug Application for tofersen, giving the drugmaker an early win in its battle for an amyotrophic lateral sclerosis (ALS) therapy.…

Continue ReadingFDA Gives Priority Review to Biogen’s Tofersen for Rare Form of ALS

Booker, Paul Introduce Senate Right to Try Bill for MDMA and Psilocybin

  • Post author:PacConAdmin
  • Post published:July 26, 2022
  • Post category:Drug Industry Daily

Sens. Cory Booker (D-N.J.) and Rand Paul (R-Ky.) introduced a bill yesterday seeking to update the Right to Try Act to permit terminally ill patients to access Schedule I drugs…

Continue ReadingBooker, Paul Introduce Senate Right to Try Bill for MDMA and Psilocybin

EMA Expert Panel Greenlights 11 New Drugs

  • Post author:PacConAdmin
  • Post published:July 25, 2022
  • Post category:Drug Industry Daily

The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended 11 new medicines for EU marketing authorizations at its July 18-21 meeting. Source: Drug Industry Daily

Continue ReadingEMA Expert Panel Greenlights 11 New Drugs

Clinical Researcher Likely to Be Nominated to Lead the National Cancer Institute

  • Post author:PacConAdmin
  • Post published:July 25, 2022
  • Post category:Drug Industry Daily

Several cancer organizations have voiced strong support for the Biden administration’s apparent pick for National Cancer Institute (NCI) director, Monica Bertagnolli, a distinguished surgical oncologist with a long career in…

Continue ReadingClinical Researcher Likely to Be Nominated to Lead the National Cancer Institute

ICMRA Seeks Global Harmony on Real-World Data

  • Post author:PacConAdmin
  • Post published:July 25, 2022
  • Post category:Drug Industry Daily

The International Coalition of Medicines Regulatory Authorities (ICMRA) has published a call to bring stakeholders together in a discussion about using real-world evidence (RWE) and real-world data (RWD) in bringing…

Continue ReadingICMRA Seeks Global Harmony on Real-World Data
  • Go to the previous page
  • 1
  • …
  • 234
  • 235
  • 236
  • 237
  • 238
  • 239
  • 240
  • …
  • 328
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.